MammaPrint Test

MammaPrint Test

This is an advanced and modern test aimed at evaluating and analyzing genes from the cancer cells. In this test a sample of breast cancer tissue is taken usually an early stage cancer is preferred, 70 genes are isolated from this sample and analyzed. This analysis is done for assessing the recurrence risk of the cancer within span of 10 years post diagnosis and detection. The results of mammprint test are quite useful and if the results are comprehended in relation to other aspects of cancer can be utilized in prescribing treatment. The results can tell us if chemotherapy radiations or what other course of therapy should be undertaken.

Candidate Eligibility for the MammaPrint Test

This test can specifically be put to use for analysis of breast cancers in early stages. It is used on stage I and stage II cancers, cancers which are invasive, growth of cancerous cells which is smaller than 5 centimeters, testing of estrogen-receptor-positive or -negative quality of the tumor growth. Also for cancers which have spread to three or lesser number of lymph nodes, this test can be undertaken.

Also the tissue to be analyzed for the MammaPrint test can be fresh or freshly frozen or even it may be treated or "fixed" tissue. In it with special treatment of certain chemicals, the genetic material is preserved.

Functioning of Mammaprint Test

This test analyses 70 genes of the body which have closest relationship with the breast cancer tissue and by this analysis, it is able to determine the recurrence probability of the cancer within a span of 10 years post treatment.

The results may be announced as high risk or a low risk result. A low risk result would mean that the recurrence risk of the cancer within 10 years is at 10% without the administration of any additional therapy apart from original. Now with hormonal therapy this risk can be lowered to 5%. A high risk result would mean that the recurrence risk of the cancer within 10 years is at 29% without the administration of any additional therapy.

The Difference between the Mammaprint Test and Oncotype DX and Mammostrat test

  • Oncotype DX test and Mammostrat test both again with the ananlysis of breast cancer genes are able to foretell the recurrence risk of that cancer.
  • The primary difference with oncotype DX test is that, apart from recurrence in early stage cancer and hormone receptor positive breast cancer it also give results for DCIS coupled with the analysis result if there is risk of occurrence of another new invasive cancer in the same afflicted breast. also it tells the doctor hoe radiation therapy would help in such a DCIS cancer. In this test activity of 21 genes is analysed and a recurrence score between 1 – 100 is calculated. A higher score would indicate a higher risk.
  • A mammostrat test also analyses early stage, hormone receptor positive breast cancer for recurrence likelihood, but it takes into account levels of 5 genes in breast cancer cells. The measurement is in risk index score, with a higher index value indicating higher risk. On the basis of this score women are categorized into segments of high risk, moderate/medium risk and high risk.
  • Thus a mammaprint test though analyses genes for recurrence of the breast cancer but the genes analyzed and the measurement is different in all three. And it helps the doctor in deciding about chemotherapy and its role in reduction and prevention of recurrence of breast cancer in the patient.
Share :
Being Breast Cancer Aware
What is Breast Cancer?
Inquiry About Breast Cancer